Abstract: The present invention provides a method for determining recent use of cannabis, including recent use within the impairment window, following administration through inhalation, the method comprising the collection of samples of exhaled breath and whole blood separated by known intervals of time, analyzing them using appropriate analytical methods, and then calculating pharmacologic parameters associated with recent cannabis use. In particular embodiments, the method is used by employers in the routine monitoring of workplace drug policy compliance among employees and in workplace accident investigations. In some embodiments, the method is utilized by law enforcement personnel to gath-er evidence in driving under the influence investigations.

Abstract: The present invention provides a method for determining recent use of cannabis in human subjects, the method comprising collecting samples of whole blood separated in time utilizing a device that collects and stores capillary blood for LC-MS/MS analysis. In particular embodiments, the method is used by law enforcement personnel to collect evidence in driving under the influence investigations. In some embodiments, the method is utilized by employers in routine monitoring of workplace drug policy compliance among employees and in workplace accident investigations.

Abstract: The present invention provides methods for alleviating menopausal symptoms as a result of chemotherapy-induced or natural menopause in a subject, the method comprising administering an effective amount of a natural product or combination of natural products tailored to a subjects specific symptoms, with an effective amount of hormonal or non-hormonal synthetic prescription medication. In particular embodiments, the natural product or combination of natural products alleviate vasomotor menopausal symptoms in a subject, while the prescription medication alleviates symptoms associated with genitourinary syndrome of menopause. In some embodiments, the natural product or combination of natural products is prepared in formulations designed for administration at different times of day.

Abstract: The present invention provides methods for modulating the immune response of a subject to a therapeutic agent, the method comprising administering an effective amount of a triphenylethylene (TRIP) compound with an effective amount of the therapeutic agent. In particular embodiments, the TRIP compound enhances the immune response of the subject to the therapeutic agent. In some embodiments, the TRIP compound is administered in different dosing schedules to provide a biphasic immunomodulation effect.

Abstract: The present invention provides methods for modulating the immune response of a subject to a therapeutic agent, the method comprising administering an effective amount of a triphenylethylene (TRIP) compound with an effective amount of the therapeutic agent. In particular embodiments, the TRIP compound enhances the immune response of the subject to the therapeutic agent. In some embodiments, the TRIP compound is administered in different dosing schedules to provide a biphasic immunomodulation effect.

Abstract: This invention relates to a method for inhibition of skin atrophy, or epithelial or mucosal atrophy in women, or to a method for treatment or prevention of symptoms related to said atrophy, said method comprising administering to the woman an effective amount of the compound of formula (I) or a geometric isomer, a stereoisomer, a pharmaceutically acceptable salt, an ester thereof or a metabolite thereof.

Abstract: This invention relates to a method for inhibition of skin atrophy, or epithelial or mucosal atrophy in women, or to a method for treatment or prevention of symptoms related to said atrophy, said method comprising administering to the woman an effective amount of the compound of formula (I) or a geometric isomer, a stereoisomer, a pharmaceutically acceptable salt, an ester thereof or a metabolite thereof.

Abstract: This invention concerns a method for the treatment of vaginal dryness or sexual dysfunction in women during or after the menopause, said method comprising administering to the woman an effective amount of the compound (deaminohydroxy)toremifene or a pharmaceutically acceptable salt or ester thereof, or a metabolite thereof.

Abstract: Transdermal preparations containing as active ingredient toremifene or one of its metabolites N-demethyltoremifene or 4-hydroxy-toremifene or their pharmaceutically acceptable non-toxic salts are useful for the treatment of cancers localized in the skin or on a short distance form the skin such as metastatic lesions of breast cancer. They may also be used in adjuvant therapy of breast cancer and in the reversal of multidrug resistance of cancer cells to cytotoxic drugs. Such transdernal preparations are of particular interest in the treatment of melanoma, lymphoma, Kaposi's sarcoma and fungoides mycosis.

Abstract: The present invention involves a method for early detection of developing tamoxifen resistance in breast cancer. Tamoxifen is the drug of choice for hormonal therapy of a first recurrence of breast cancer, but its use is associated eventually with emergence of resistant tumors. Whereas initial treatment is usually followed by tumor regression, resistant tumors may actually resume growth under continued tamoxifen treatment. Because such growth may actually be augmented by the tamoxifen, it is essential to identify the onset of resistance as early as possible so alternative therapy may be promptly instituted. Monitoring increased levels of estrogenic tamoxifen isomers or estrogenic tamoxifen metabolites signals developing resistance.

Abstract: This invention relates to the use of a compound comprising toremifene or its metabolites N-demethyltoremifene or 4-hydroxytoremifene or its non-toxic pharmaceutically acceptable salts for the reversal of multidrug resistance of cancer cells to cytotoxic drugs in the treatment of cancer with such cytotoxic drugs.